IRWD:NASDAQ
Ironwood Pharmaceuticals, Inc.
$4.87
arrow_upward
+1.25%(+0.060) 1D
$4.88
arrow_upward
+0.17% (+0.0081)bedtimeAfter hours
Closed: Nov 11, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IRWD...
Open
$4.81
High
$4.93
Low
$4.74
Mkt. cap
806.23M
Avg. vol.
2.17M
Volume
0.00
P/E ratio
5.48
52-wk high
$5.78
52-wk low
$2.86
EPS
$0.89
Beta
0.25
Shares outstanding
165.55M
No. of employees
100
Open
$4.81
High
$4.93
Low
$4.74
Mkt. cap
806.23M
Avg. vol.
2.17M
Volume
0.00
P/E ratio
5.48
52-wk high
$5.78
52-wk low
$2.86
EPS
$0.89
Beta
0.25
Shares outstanding
165.55M
No. of employees
100
News stories
From web sources and news partners
Benzinga
·
30 minutes ago
Stock Market: Will S&P 500 Open Up or Down Today?
TradingView
·
1 hour ago
S&P 500, underlying bullish trend remains intact for SP:SPX by Swissquote
Eurasia Business News
·
10 hours ago
Stock Market Today: Dow Jones, Nasdaq, S&P 500 Rally on November 11, 2026; Oil Rises, Gold Slips
Traders Union
·
12 hours ago
S&P 500 rises around 1.5% as artificial intelligence optimism and CoreWeave earnings fuel rebound
Profile
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler's diarrhea.
By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
About Ironwood Pharmaceuticals, Inc.
CEO-
Employees100
Founded1998
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteironwoodpharma.com